Gritstone bio Inc

NASDAQ:GRTS

Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 193 full-time employees. The company went IPO on 2018-09-28. The firm discover, develop, manufacture and deliver next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The firm has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate that are collaborating on with Gilead Sciences, Inc. The Company’s product candidates include GRT-C907 (ChAd)/R908 (samRNA), GRT- C909 (ChAd)/R910 (samRNA), GRT-C909 (ChAd)/R910 (samRNA), GRT-R914 (samRNA), GRT-R912 (samRNA) and GRT-R918 (samRNA).